(NASDAQ: EXEL) Exelixis's forecast annual revenue growth rate of 10.11% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Exelixis's revenue in 2025 is $2,298,922,000.On average, 10 Wall Street analysts forecast EXEL's revenue for 2025 to be $638,408,719,939, with the lowest EXEL revenue forecast at $619,047,795,600, and the highest EXEL revenue forecast at $705,114,528,768. On average, 10 Wall Street analysts forecast EXEL's revenue for 2026 to be $723,642,056,603, with the lowest EXEL revenue forecast at $679,589,033,760, and the highest EXEL revenue forecast at $835,681,799,066.
In 2027, EXEL is forecast to generate $843,272,361,332 in revenue, with the lowest revenue forecast at $728,949,232,440 and the highest revenue forecast at $981,177,120,612.